Advances in the Therapy of Advanced Ovarian Cancer-Special Emphasis on the PD1/PDL1 Pathway

Advances in the Therapy of Advanced Ovarian Cancer-Special Emphasis on the PD1/PDL1 Pathway

Authored By Kulvinder Kochar Kaur, Ovarian Cancer gets diagnosed in advanced stage in 75% of patient and thus remains one of the most lethal gynecological malignancies. Despite 80% patients being responsive to platinum based chemotherapies to start with most relapse finally. Hence need of the hour is to find more effective immunotherapy’s to be added to these CRT. Programmed cell death1 (PD1) -PDL1 is an important immune pathway which is discussed in detail along with role of nivelumab (a monoclonal antibody against PD1) and addition of other immunotherapy’s like bevacizumab, Olafarib (A PARP (polyadenosine diphosphate (ADP)-ribose- inhibitor), C edinarib (a VEGF123 inhibitor) etc to increase five year survival. Reasons of why success not obtained as expected is further sought through Effect of IFNγ on PDL1 pathway and different NK cellular phenotypes is further analyzed besides role of NACT (neoadjunctive chemotherapy) on induction of immune response.

Comments

Popular posts from this blog

Controlling Informative Features for Improved Accuracy and Faster Predictions in Omentum Cancer Models

Biological Samples as a Tool for Analysis of Metals in Serum of Cataract Patients-Current Trends in Biomedical Engineering & Biosciences-Juniper Publishers

Research as a Tool in the Elimination of Onchocerciasis_Juniper Publishers